Bluebird Bio
Bluebird Bio, Inc.
455 Grand Union Boulevard
Somerville, MA 02145
Phone: (339) 499 9300Website: https://www.bluebirdbio.com/Careers: www.bluebirdbio.com/careers
Latest news
- FDA Approves Lyfgenia (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
8 December 2023 - bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
24 April 2023 - FDA Approves Skysona (elivaldogene autotemcel) Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
18 September 2022 - FDA Approves Zynteglo (betibeglogene autotemcel) Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
17 August 2022
Drugs Associated with Bluebird Bio, Inc.
Bluebird Bio, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Lyfgenia
Generic name: lovotibeglogene autotemcel Drug class: miscellaneous uncategorized agents |
||
|
Skysona
Generic name: elivaldogene autotemcel Drug class: miscellaneous uncategorized agents |
||
|
Zynteglo
Generic name: betibeglogene autotemcel Drug class: miscellaneous uncategorized agents |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
